Phase 4 N=119 TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients
Vaccine Responsiveness in Allergy · Vaccine Responsiveness During Allergy De-sensitization Treatment
Primary: Humoral TBE Immunity — 317.90; 250.10; 282.20 titer
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=16 The Effects of Immunotherapy in the Nose
Rhinitis, Allergic, Seasonal
Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts
Phase 1 N=259 Contact Sensitization Potential of 828 Ointment
Healthy Volunteers
Primary: Number of Participants That Exhibited a Score Less Than 1.5 on the Jordan-King Scale — 205 participants
Phase 2 N=58 Allergy Immunotherapy for the Reduction of Asthma
Wheezing · Asthma · Allergy
Primary: Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months) — 21.95; 25.68; 27.72; 27.85 score on a scale — p=0.38
N/A N=45 Nasal Allergen Challenge in Rhinitic Subjects
Asthma · Allergic Rhinitis
Primary: Change in Sputum Eosinophils Following Allergen Challenge — 5.6; 2.0; 6.0; 1.3 percentage of sputum eosinophils
Early Phase 1 N=12 The Effect of Allergen Inhalation on Sputum Myeloid and Plasmacytoid Dendritic Cells in Mild Atopic Asthmatics
Asthma
Primary: The Primary Outcome Measure for This Study is the Number of Sputum Myeloid Dendritic Cells — 32800; 89100 number of cells/g of sputum
Phase 2 N=12 Subcutaneous Immunotherapy for Mouse in Adults
Asthma · Perennial Allergic Rhinitis
Primary: Number of Reported Adverse Events (AEs) — 9; 1; 1; 2 Events
Phase 1 N=48 Subcutaneous Immunotherapy in Patients Sensitized to Dermatophagoides Pteronyssinus (DPT)
Allergic Rhinoconjunctivitis
Primary: Number and Seriousness of Both Local and Systemic Adverse Reactions — 2; 1; 0; 1 adverse reactions number
N/A N=434 Evaluating Symptom Control in in Allergic Rhinitis at Three Years After Starting Immunotherapy
Allergic Rhinitis
Primary: Current Medication Use Three Years After Diagnosis of AR — 61; 29 percentage of participants
Phase 2 N=75 Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
Peanut Hypersensitivity · Food Hypersensitivity · Hypersensitivity
Primary: Percentage of Subjects With a Successful Treatment Response — 12.0; 45.8; 48.0 percentage of participants — p=0.005
Phase 2 N=54 Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance
Peanut Hypersensitivity · Food Hypersensitivity · Food Allergy
Primary: Population Sensitization Threshold in mg Peanut Protein Predicted to Provoke Reactions in 5% of the Peanut-allergic Population — 160; 300 mg
Phase 2 N=51 Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study
Asthma · Allergic Sensitization
Primary: Number of Participants With Allergic Sensitization at Month 36 Status Post Treatment Completion — 22; 19 participants — p=0.28
Phase 2 N=13 Xolair Enhances Oral Desensitization in Peanut Allergic Patients
Peanut Allergy
Primary: Number of Participants That Tolerated Rapid Oral Peanut Desensitization to a Dose of 500 mg Peanut Flour (Cumulative Dose, 1,000 mg) — 13 participants
Phase 4 N=275 Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma
Allergic Asthma
Primary: Number of Participants With Systemic Allergic Reactions (SAR) to Specific Immunotherapy (SIT) — 32; 17; 49 participants
Phase 2 N=20 Mechanisms of Desensitization During Peanut Oral Immunotherapy
Food Hypersensitivity
Primary: Percentage of Subjects Who Develop Desensitization — 81.25 percentage of participants
Phase 2 N=22 Clinical Evaluation of Lyral® Dose Response Study
Contact Dermatitis
Primary: Number of Participants With Positive Patch Test Responses — 14; 12; 11; 0 participants
N/A N=18 Immune Dysfunction in Allergic Asthma
Asthma
Primary: Anti-KLH Antibody. This is Measured by ELISA and Expressed as ELISA Units Which Are Derived by Dilution of Serum Samples Until the Result Falls on a Linear Portion of…
Phase 4 N=98 Comparability and Standardization of Controlled Allergen Challenge Facilities
Allergic Rhinitis
Primary: Comparison of TRSS From Baseline Between the EEU and BRC in the Cetirizine 10 mg and Placebo Groups. — 11.9; 11.7; 11.5; 10.8 score on a scale
N/A N=81 SPT for Sensitization of Collagen Dressing
Allergy Skin · Allergic Skin Reaction
Primary: Wheal Measurement — 0; 7.91; 0.32 mm
Phase 2 N=151 Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense
Allergic Rhinoconjunctivitis
Primary: Variation of the Concentration of Phleum Pratense Extract Needed to Produce a Positive Nasal Provocation Test From Baseline (V0) to Final Visit (FV). — 0.493; 0.275…
Phase 2 N=73 Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
Food Allergy · Peanut Allergy
Primary: Percentage of Children That Tolerate the Full Challenge — 100; 21 percentage of participants
Phase 2 N=36 Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
Peanut Allergy · Food Allergy
Primary: Tolerance of 2000 mg 6 Weeks After Last Dose of Omalizumab/Placebo — 23; 1 Participants
Phase 2 N=28 Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics
Asthma
Primary: Difference in Expression of Epithelial miRNAs (in Read Counts) 24 Hours After Allergen-challenge as Compared to 24 Hours After Diluent Challenge in Participants With…
N/A N=8,790 Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy (MK-7243-022)
Perennial Allergic Rhinitis · Seasonal Allergic Rhinitis
Primary: Percentage of Participants Advised to Start AIT Who Elected Subcutaneous Immunotherapy (SCIT) Shots or Sublingual Immunotherapy (SLIT) Drops — 28.2; 8.0 percentage of…
N/A N=19 Mast Cell Activation Test in Allergic Disease
Asthma · Mastocytosis · Mast Cell Activation Syndrome
Primary: Mast Cell Activation Test Results for Validation Group — 6; 2; 0; 4 Participants
N/A N=7 High Threshold Peanut Challenge Study
Peanut Allergy
Primary: Consistency of High Threshold Reactivity — 6 Participants
Phase 2 N=60 Multi Immunotherapy to Test Tolerance and Xolair
Food Allergy
Primary: The Number of Participants Able to Tolerate an Oral Food Challenge to 2,000 mg at Least of 2 Allergens at Week 36 (i.e. the End of the Randomized Withdrawal/Tolerance…
Phase 2 N=31 A Novel Biologic Therapy for Perennial Allergic Rhinitis
Allergic Rhinitis
Primary: Daily Combined Score (DCS) — -4.41; -1.61 DCS (daily combined score)
Phase 1 N=27 Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
Birch Pollen Allergy
Primary: Treatment Emergent Adverse Events — 13; 3; 81; 2 number of adverse events per arm
N/A N=24 Randomized Evaluation of Ten Allergy Skin Prick Test Devices
Allergic Rhinitis · Asthma · Food Allergy
Primary: Wheal Response — 6.8 mm